Global Next-Generation Breast Cancer Diagnostic and Screening Market Size, Status and Forecast 2024-2031

Report ID: 919059 | Published Date: Sep 2024 | No. of Page: 118 | Base Year: 2023 | Rating: 4.8 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
        1.2.2 Real-Time PCR (q-PCR)
        1.2.3 Immunohistochemistry (IHC)
        1.2.4 Next-Generation Sequencing (NGS)
        1.2.5 Fluorescent In-Situ Hybridization (FISH)
    1.3 Market by Application
        1.3.1 Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Application: 2016 VS 2021 VS 2027
        1.3.2 Hospital-associated Labs
        1.3.3 Cancer Research Institutes
        1.3.4 Diagnostic Centers
    1.4 Study Objectives
    1.5 Years Considered

2 Global Growth Trends
    2.1 Global Next-Generation Breast Cancer Diagnostic and Screening Market Perspective (2016-2027)
    2.2 Next-Generation Breast Cancer Diagnostic and Screening Growth Trends by Regions
        2.2.1 Next-Generation Breast Cancer Diagnostic and Screening Market Size by Regions: 2016 VS 2021 VS 2027
        2.2.2 Next-Generation Breast Cancer Diagnostic and Screening Historic Market Share by Regions (2016-2021)
        2.2.3 Next-Generation Breast Cancer Diagnostic and Screening Forecasted Market Size by Regions (2022-2027)
    2.3 Next-Generation Breast Cancer Diagnostic and Screening Industry Dynamic
        2.3.1 Next-Generation Breast Cancer Diagnostic and Screening Market Trends
        2.3.2 Next-Generation Breast Cancer Diagnostic and Screening Market Drivers
        2.3.3 Next-Generation Breast Cancer Diagnostic and Screening Market Challenges
        2.3.4 Next-Generation Breast Cancer Diagnostic and Screening Market Restraints

3 Competition Landscape by Key Players
    3.1 Global Top Next-Generation Breast Cancer Diagnostic and Screening Players by Revenue
        3.1.1 Global Top Next-Generation Breast Cancer Diagnostic and Screening Players by Revenue (2016-2021)
        3.1.2 Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share by Players (2016-2021)
    3.2 Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    3.3 Players Covered: Ranking by Next-Generation Breast Cancer Diagnostic and Screening Revenue
    3.4 Global Next-Generation Breast Cancer Diagnostic and Screening Market Concentration Ratio
        3.4.1 Global Next-Generation Breast Cancer Diagnostic and Screening Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Next-Generation Breast Cancer Diagnostic and Screening Revenue in 2020
    3.5 Next-Generation Breast Cancer Diagnostic and Screening Key Players Head office and Area Served
    3.6 Key Players Next-Generation Breast Cancer Diagnostic and Screening Product Solution and Service
    3.7 Date of Enter into Next-Generation Breast Cancer Diagnostic and Screening Market
    3.8 Mergers & Acquisitions, Expansion Plans

4 Next-Generation Breast Cancer Diagnostic and Screening Breakdown Data by Type
    4.1 Global Next-Generation Breast Cancer Diagnostic and Screening Historic Market Size by Type (2016-2021)
    4.2 Global Next-Generation Breast Cancer Diagnostic and Screening Forecasted Market Size by Type (2022-2027)

5 Next-Generation Breast Cancer Diagnostic and Screening Breakdown Data by Application
    5.1 Global Next-Generation Breast Cancer Diagnostic and Screening Historic Market Size by Application (2016-2021)
    5.2 Global Next-Generation Breast Cancer Diagnostic and Screening Forecasted Market Size by Application (2022-2027)

6 North America
    6.1 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size (2016-2027)
    6.2 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type
        6.2.1 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2016-2021)
        6.2.2 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2022-2027)
        6.2.3 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2016-2027)
    6.3 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application
        6.3.1 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2016-2021)
        6.3.2 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2022-2027)
        6.3.3 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2016-2027)
    6.4 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country
        6.4.1 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2016-2021)
        6.4.2 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2022-2027)
        6.4.3 United States
        6.4.4 Canada

7 Europe
    7.1 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size (2016-2027)
    7.2 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type
        7.2.1 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2016-2021)
        7.2.2 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2022-2027)
        7.2.3 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2016-2027)
    7.3 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application
        7.3.1 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2016-2021)
        7.3.2 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2022-2027)
        7.3.3 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2016-2027)
    7.4 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country
        7.4.1 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2016-2021)
        7.4.2 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2022-2027)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic

8 Asia-Pacific
    8.1 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size (2016-2027)
    8.2 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type
        8.2.1 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2016-2021)
        8.2.2 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2022-2027)
        8.2.3 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2016-2027)
    8.3 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application
        8.3.1 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2016-2021)
        8.3.2 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2022-2027)
        8.3.3 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2016-2027)
    8.4 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region
        8.4.1 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region (2016-2021)
        8.4.2 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region (2022-2027)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia

9 Latin America
    9.1 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size (2016-2027)
    9.2 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type
        9.2.1 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2016-2021)
        9.2.2 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2022-2027)
        9.2.3 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2016-2027)
    9.3 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application
        9.3.1 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2016-2021)
        9.3.2 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2022-2027)
        9.3.3 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2016-2027)
    9.4 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country
        9.4.1 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2016-2021)
        9.4.2 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2022-2027)
        9.4.3 Mexico
        9.4.4 Brazil

10 Middle East & Africa
    10.1 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size (2016-2027)
    10.2 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type
        10.2.1 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2016-2021)
        10.2.2 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2022-2027)
        10.2.3 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2016-2027)
    10.3 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application
        10.3.1 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2016-2021)
        10.3.2 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2022-2027)
        10.3.3 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2016-2027)
    10.4 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country
        10.4.1 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2016-2021)
        10.4.2 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2022-2027)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE

11 Key Players Profiles
    11.1 Abbott Laboratories
        11.1.1 Abbott Laboratories Company Details
        11.1.2 Abbott Laboratories Business Overview
        11.1.3 Abbott Laboratories Next-Generation Breast Cancer Diagnostic and Screening Introduction
        11.1.4 Abbott Laboratories Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2016-2021)
        11.1.5 Abbott Laboratories Recent Development
    11.2 Agendia
        11.2.1 Agendia Company Details
        11.2.2 Agendia Business Overview
        11.2.3 Agendia Next-Generation Breast Cancer Diagnostic and Screening Introduction
        11.2.4 Agendia Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2016-2021)
        11.2.5 Agendia Recent Development
    11.3 Agilent Technologies
        11.3.1 Agilent Technologies Company Details
        11.3.2 Agilent Technologies Business Overview
        11.3.3 Agilent Technologies Next-Generation Breast Cancer Diagnostic and Screening Introduction
        11.3.4 Agilent Technologies Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2016-2021)
        11.3.5 Agilent Technologies Recent Development
    11.4 Ambry Genetics
        11.4.1 Ambry Genetics Company Details
        11.4.2 Ambry Genetics Business Overview
        11.4.3 Ambry Genetics Next-Generation Breast Cancer Diagnostic and Screening Introduction
        11.4.4 Ambry Genetics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2016-2021)
        11.4.5 Ambry Genetics Recent Development
    11.5 Biocept
        11.5.1 Biocept Company Details
        11.5.2 Biocept Business Overview
        11.5.3 Biocept Next-Generation Breast Cancer Diagnostic and Screening Introduction
        11.5.4 Biocept Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2016-2021)
        11.5.5 Biocept Recent Development
    11.6 Biotheranostics
        11.6.1 Biotheranostics Company Details
        11.6.2 Biotheranostics Business Overview
        11.6.3 Biotheranostics Next-Generation Breast Cancer Diagnostic and Screening Introduction
        11.6.4 Biotheranostics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2016-2021)
        11.6.5 Biotheranostics Recent Development
    11.7 Centogene
        11.7.1 Centogene Company Details
        11.7.2 Centogene Business Overview
        11.7.3 Centogene Next-Generation Breast Cancer Diagnostic and Screening Introduction
        11.7.4 Centogene Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2016-2021)
        11.7.5 Centogene Recent Development
    11.8 Danaher Corporation
        11.8.1 Danaher Corporation Company Details
        11.8.2 Danaher Corporation Business Overview
        11.8.3 Danaher Corporation Next-Generation Breast Cancer Diagnostic and Screening Introduction
        11.8.4 Danaher Corporation Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2016-2021)
        11.8.5 Danaher Corporation Recent Development
    11.9 EXACT Sciences Corporation
        11.9.1 EXACT Sciences Corporation Company Details
        11.9.2 EXACT Sciences Corporation Business Overview
        11.9.3 EXACT Sciences Corporation Next-Generation Breast Cancer Diagnostic and Screening Introduction
        11.9.4 EXACT Sciences Corporation Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2016-2021)
        11.9.5 EXACT Sciences Corporation Recent Development
    11.10 Roche Holding AG
        11.10.1 Roche Holding AG Company Details
        11.10.2 Roche Holding AG Business Overview
        11.10.3 Roche Holding AG Next-Generation Breast Cancer Diagnostic and Screening Introduction
        11.10.4 Roche Holding AG Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2016-2021)
        11.10.5 Roche Holding AG Recent Development
    11.11 Fulgent Genetics
        11.11.1 Fulgent Genetics Company Details
        11.11.2 Fulgent Genetics Business Overview
        11.11.3 Fulgent Genetics Next-Generation Breast Cancer Diagnostic and Screening Introduction
        11.11.4 Fulgent Genetics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2016-2021)
        11.11.5 Fulgent Genetics Recent Development
    11.12 Illumina
        11.12.1 Illumina Company Details
        11.12.2 Illumina Business Overview
        11.12.3 Illumina Next-Generation Breast Cancer Diagnostic and Screening Introduction
        11.12.4 Illumina Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2016-2021)
        11.12.5 Illumina Recent Development
    11.13 Invitae
        11.13.1 Invitae Company Details
        11.13.2 Invitae Business Overview
        11.13.3 Invitae Next-Generation Breast Cancer Diagnostic and Screening Introduction
        11.13.4 Invitae Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2016-2021)
        11.13.5 Invitae Recent Development
    11.14 Lucence Diagnostics Pte Ltd
        11.14.1 Lucence Diagnostics Pte Ltd Company Details
        11.14.2 Lucence Diagnostics Pte Ltd Business Overview
        11.14.3 Lucence Diagnostics Pte Ltd Next-Generation Breast Cancer Diagnostic and Screening Introduction
        11.14.4 Lucence Diagnostics Pte Ltd Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2016-2021)
        11.14.5 Lucence Diagnostics Pte Ltd Recent Development
    11.15 Myriad Genetics
        11.15.1 Myriad Genetics Company Details
        11.15.2 Myriad Genetics Business Overview
        11.15.3 Myriad Genetics Next-Generation Breast Cancer Diagnostic and Screening Introduction
        11.15.4 Myriad Genetics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2016-2021)
        11.15.5 Myriad Genetics Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details
List of Tables
    Table 1. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
    Table 2. Key Players of Real-Time PCR (q-PCR)
    Table 3. Key Players of Immunohistochemistry (IHC)
    Table 4. Key Players of Next-Generation Sequencing (NGS)
    Table 5. Key Players of Fluorescent In-Situ Hybridization (FISH)
    Table 6. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
    Table 7. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
    Table 8. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size by Regions (2016-2021) & (US$ Million)
    Table 9. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Regions (2016-2021)
    Table 10. Global Next-Generation Breast Cancer Diagnostic and Screening Forecasted Market Size by Regions (2022-2027) & (US$ Million)
    Table 11. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Regions (2022-2027)
    Table 12. Next-Generation Breast Cancer Diagnostic and Screening Market Trends
    Table 13. Next-Generation Breast Cancer Diagnostic and Screening Market Drivers
    Table 14. Next-Generation Breast Cancer Diagnostic and Screening Market Challenges
    Table 15. Next-Generation Breast Cancer Diagnostic and Screening Market Restraints
    Table 16. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue by Players (2016-2021) & (US$ Million)
    Table 17. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Players (2016-2021)
    Table 18. Global Top Next-Generation Breast Cancer Diagnostic and Screening Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Next-Generation Breast Cancer Diagnostic and Screening as of 2020)
    Table 19. Ranking of Global Top Next-Generation Breast Cancer Diagnostic and Screening Companies by Revenue (US$ Million) in 2020
    Table 20. Global 5 Largest Players Market Share by Next-Generation Breast Cancer Diagnostic and Screening Revenue (CR5 and HHI) & (2016-2021)
    Table 21. Key Players Headquarters and Area Served
    Table 22. Key Players Next-Generation Breast Cancer Diagnostic and Screening Product Solution and Service
    Table 23. Date of Enter into Next-Generation Breast Cancer Diagnostic and Screening Market
    Table 24. Mergers & Acquisitions, Expansion Plans
    Table 25. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2016-2021) (US$ Million)
    Table 26. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share by Type (2016-2021)
    Table 27. Global Next-Generation Breast Cancer Diagnostic and Screening Forecasted Market Size by Type (2022-2027) (US$ Million)
    Table 28. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share by Type (2022-2027) & (US$ Million)
    Table 29. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size Share by Application (2016-2021) & (US$ Million)
    Table 30. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share by Application (2016-2021)
    Table 31. Global Next-Generation Breast Cancer Diagnostic and Screening Forecasted Market Size by Application (2022-2027) (US$ Million)
    Table 32. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share by Application (2022-2027) & (US$ Million)
    Table 33. North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2016-2021) (US$ Million)
    Table 34. North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2022-2027) & (US$ Million)
    Table 35. North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2016-2021) (US$ Million)
    Table 36. North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2022-2027) & (US$ Million)
    Table 37. North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2016-2021) & (US$ Million) 
    Table 38. North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2022-2027) & (US$ Million) 
    Table 39. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2016-2021) (US$ Million)
    Table 40. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2022-2027) & (US$ Million)
    Table 41. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2016-2021) (US$ Million)
    Table 42. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2022-2027) & (US$ Million)
    Table 43. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2016-2021) & (US$ Million) 
    Table 44. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2022-2027) & (US$ Million) 
    Table 45. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2016-2021) (US$ Million)
    Table 46. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2022-2027) & (US$ Million)
    Table 47. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2016-2021) (US$ Million)
    Table 48. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2022-2027) & (US$ Million)
    Table 49. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region (2016-2021) & (US$ Million) 
    Table 50. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region (2022-2027) & (US$ Million) 
    Table 51. Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2016-2021) (US$ Million)
    Table 52. Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2022-2027) & (US$ Million)
    Table 53. Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2016-2021) (US$ Million)
    Table 54. Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2022-2027) & (US$ Million)
    Table 55. Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2016-2021) & (US$ Million) 
    Table 56. Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2022-2027) & (US$ Million) 
    Table 57. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2016-2021) (US$ Million)
    Table 58. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2022-2027) & (US$ Million)
    Table 59. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2016-2021) (US$ Million)
    Table 60. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2022-2027) & (US$ Million)
    Table 61. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2016-2021) & (US$ Million) 
    Table 62. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2022-2027) & (US$ Million) 
    Table 63. Abbott Laboratories Company Details
    Table 64. Abbott Laboratories Business Overview
    Table 65. Abbott Laboratories Next-Generation Breast Cancer Diagnostic and Screening Product
    Table 66. Abbott Laboratories Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2016-2021) & (US$ Million)
    Table 67. Abbott Laboratories Recent Development
    Table 68. Agendia Company Details
    Table 69. Agendia Business Overview
    Table 70. Agendia Next-Generation Breast Cancer Diagnostic and Screening Product
    Table 71. Agendia Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2016-2021) & (US$ Million)
    Table 72. Agendia Recent Development
    Table 73. Agilent Technologies Company Details
    Table 74. Agilent Technologies Business Overview
    Table 75. Agilent Technologies Next-Generation Breast Cancer Diagnostic and Screening Product
    Table 76. Agilent Technologies Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2016-2021) & (US$ Million)
    Table 77. Agilent Technologies Recent Development
    Table 78. Ambry Genetics Company Details
    Table 79. Ambry Genetics Business Overview
    Table 80. Ambry Genetics Next-Generation Breast Cancer Diagnostic and Screening Product
    Table 81. Ambry Genetics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2016-2021) & (US$ Million)
    Table 82. Ambry Genetics Recent Development
    Table 83. Biocept Company Details
    Table 84. Biocept Business Overview
    Table 85. Biocept Next-Generation Breast Cancer Diagnostic and Screening Product
    Table 86. Biocept Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2016-2021) & (US$ Million)
    Table 87. Biocept Recent Development
    Table 88. Biotheranostics Company Details
    Table 89. Biotheranostics Business Overview
    Table 90. Biotheranostics Next-Generation Breast Cancer Diagnostic and Screening Product
    Table 91. Biotheranostics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2016-2021) & (US$ Million)
    Table 92. Biotheranostics Recent Development
    Table 93. Centogene Company Details
    Table 94. Centogene Business Overview
    Table 95. Centogene Next-Generation Breast Cancer Diagnostic and Screening Product
    Table 96. Centogene Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2016-2021) & (US$ Million)
    Table 97. Centogene Recent Development
    Table 98. Danaher Corporation Company Details
    Table 99. Danaher Corporation Business Overview
    Table 100. Danaher Corporation Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2016-2021) & (US$ Million)
    Table 101. Danaher Corporation Recent Development
    Table 102. EXACT Sciences Corporation Company Details
    Table 103. EXACT Sciences Corporation Business Overview
    Table 104. EXACT Sciences Corporation Next-Generation Breast Cancer Diagnostic and Screening Product
    Table 105. EXACT Sciences Corporation Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2016-2021) & (US$ Million)
    Table 106. EXACT Sciences Corporation Recent Development
    Table 107. Roche Holding AG Company Details
    Table 108. Roche Holding AG Business Overview
    Table 109. Roche Holding AG Next-Generation Breast Cancer Diagnostic and Screening Product
    Table 110. Roche Holding AG Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2016-2021) & (US$ Million)
    Table 111. Roche Holding AG Recent Development
    Table 112. Fulgent Genetics Company Details
    Table 113. Fulgent Genetics Business Overview
    Table 114. Fulgent Genetics Next-Generation Breast Cancer Diagnostic and Screening Product
    Table 115. Fulgent Genetics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2016-2021) & (US$ Million)
    Table 116. Fulgent Genetics Recent Development
    Table 117. Illumina Company Details
    Table 118. Illumina Business Overview
    Table 119. Illumina Next-Generation Breast Cancer Diagnostic and Screening Product
    Table 120. Illumina Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2016-2021) & (US$ Million)
    Table 121. Illumina Recent Development
    Table 122. Invitae Company Details
    Table 123. Invitae Business Overview
    Table 124. Invitae Next-Generation Breast Cancer Diagnostic and Screening Product
    Table 125. Invitae Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2016-2021) & (US$ Million)
    Table 126. Invitae Recent Development
    Table 127. Lucence Diagnostics Pte Ltd Company Details
    Table 128. Lucence Diagnostics Pte Ltd Business Overview
    Table 129. Lucence Diagnostics Pte Ltd Next-Generation Breast Cancer Diagnostic and Screening Product
    Table 130. Lucence Diagnostics Pte Ltd Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2016-2021) & (US$ Million)
    Table 131. Lucence Diagnostics Pte Ltd Recent Development
    Table 132. Myriad Genetics Company Details
    Table 133. Myriad Genetics Business Overview
    Table 134. Myriad Genetics Next-Generation Breast Cancer Diagnostic and Screening Product
    Table 135. Myriad Genetics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2016-2021) & (US$ Million)
    Table 136. Myriad Genetics Recent Development
    Table 137. Research Programs/Design for This Report
    Table 138. Key Data Information from Secondary Sources
    Table 139. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Type: 2020 VS 2027
    Figure 2. Real-Time PCR (q-PCR) Features
    Figure 3. Immunohistochemistry (IHC) Features
    Figure 4. Next-Generation Sequencing (NGS) Features
    Figure 5. Fluorescent In-Situ Hybridization (FISH) Features
    Figure 6. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Application: 2020 VS 2027
    Figure 7. Hospital-associated Labs Case Studies
    Figure 8. Cancer Research Institutes Case Studies
    Figure 9. Diagnostic Centers Case Studies
    Figure 10. Next-Generation Breast Cancer Diagnostic and Screening Report Years Considered
    Figure 11. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size (US$ Million), Year-over-Year: 2016-2027
    Figure 12. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size (US$ Million), 2016 VS 2021 VS 2027
    Figure 13. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Regions: 2020 VS 2027
    Figure 14. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Regions (2022-2027)
    Figure 15. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Players in 2020
    Figure 16. Global Top Next-Generation Breast Cancer Diagnostic and Screening Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Next-Generation Breast Cancer Diagnostic and Screening as of 2020
    Figure 17. The Top 10 and 5 Players Market Share by Next-Generation Breast Cancer Diagnostic and Screening Revenue in 2020
    Figure 18. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share by Type (2016-2021)
    Figure 19. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share by Type (2022-2027)
    Figure 20. North America Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 21. North America Next-Generation Breast Cancer Diagnostic and Screening Market Share by Type (2016-2027)
    Figure 22. North America Next-Generation Breast Cancer Diagnostic and Screening Market Share by Application (2016-2027)
    Figure 23. North America Next-Generation Breast Cancer Diagnostic and Screening Market Share by Country (2016-2027)
    Figure 24. United States Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 25. Canada Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 26. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 27. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Share by Type (2016-2027)
    Figure 28. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Share by Application (2016-2027)
    Figure 29. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Share by Country (2016-2027)
    Figure 30. Germany Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 31. France Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 32. U.K. Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 33. Italy Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 34. Russia Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 35. Nordic Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 36. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 37. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Share by Type (2016-2027)
    Figure 38. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Share by Application (2016-2027)
    Figure 39. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Share by Region (2016-2027)
    Figure 40. China Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 41. Japan Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 42. South Korea Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 43. Southeast Asia Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 44. India Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 45. Australia Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 46. Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 47. Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Share by Type (2016-2027)
    Figure 48. Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Share by Application (2016-2027)
    Figure 49. Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Share by Country (2016-2027)
    Figure 50. Mexico Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 51. Brazil Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 52. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 53. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Share by Type (2016-2027)
    Figure 54. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Share by Application (2016-2027)
    Figure 55. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Share by Country (2016-2027)
    Figure 56. Turkey Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 57. Saudi Arabia Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 58. UAE Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 59. Abbott Laboratories Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2016-2021)
    Figure 60. Agendia Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2016-2021)
    Figure 61. Agilent Technologies Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2016-2021)
    Figure 62. Ambry Genetics Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2016-2021)
    Figure 63. Biocept Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2016-2021)
    Figure 64. Biotheranostics Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2016-2021)
    Figure 65. Centogene Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2016-2021)
    Figure 66. Danaher Corporation Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2016-2021)
    Figure 67. EXACT Sciences Corporation Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2016-2021)
    Figure 68. Roche Holding AG Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2016-2021)
    Figure 69. Fulgent Genetics Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2016-2021)
    Figure 70. Illumina Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2016-2021)
    Figure 71. Invitae Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2016-2021)
    Figure 72. Lucence Diagnostics Pte Ltd Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2016-2021)
    Figure 73. Myriad Genetics Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2016-2021)
    Figure 74. Bottom-up and Top-down Approaches for This Report
    Figure 75. Data Triangulation
    Figure 76. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Abbott Laboratories
Agendia
Agilent Technologies
Ambry Genetics
Biocept
Biotheranostics
Centogene
Danaher Corporation
EXACT Sciences Corporation
Roche Holding AG
Fulgent Genetics
Illumina
Invitae
Lucence Diagnostics Pte Ltd
Myriad Genetics
Frequently Asked Questions
Next-Generation Breast Cancer Diagnostic and Screening report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Next-Generation Breast Cancer Diagnostic and Screening report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Next-Generation Breast Cancer Diagnostic and Screening report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports